Asset Details
Do you wish to reserve the book?
Zidovudine Improves Response to Pneumococcal Vaccine among Persons with AIDS and AIDS-Related Complex
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Zidovudine Improves Response to Pneumococcal Vaccine among Persons with AIDS and AIDS-Related Complex
Do you wish to request the book?
Zidovudine Improves Response to Pneumococcal Vaccine among Persons with AIDS and AIDS-Related Complex
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Zidovudine Improves Response to Pneumococcal Vaccine among Persons with AIDS and AIDS-Related Complex
1991
Overview
Antibody responses to 23-valent pneumococcal vaccine were studied in 38 individuals infected with human immunodeficiency virus (HIV), including 6 with asymptomatic infection, 24 with AIDS or AIDS-related complex (ARC) receiving treatment with zidovudine, and 8 untreated AIDS/ARC patients. Antibody responses were significantly higher for asymptomatic persons (aggregate geometric mean, 972 ng of antibody nitrogen (AbN)/ml; P < .001) and AIDS/ARC patients receiving a median of 12 weeks (range, 4–54) of zidovudine therapy (mean, 369 ng of AbN/ml; P < .001) when compared with untreated AIDS/ARC patients. Antibody responses among zidovudine-treated AIDS/ARC patients were independent of the dose (mean, 629.2 mgt day; range, 100–1200 mg) or duration of zidovudine therapy, For zidovudine-treated AIDS/ ARC patients, persistence of an aggregate antibody response 8 months after vaccination was associated with survival at 14 months after vaccination, whereas waning of response was not. Pneumococcal vaccine should be administered as early as possible in the course ofHIV infection. Immunization should be delayed for at least 4 weeks for AIDS/ARC patients initiating zidovudine therapy.
Publisher
The University of Chicago Press,University of Chicago Press
Subject
Acquired Immunodeficiency Syndrome - complications
/ Acquired Immunodeficiency Syndrome - drug therapy
/ Acquired Immunodeficiency Syndrome - immunology
/ Adult
/ AIDS
/ AIDS-Related Complex - complications
/ AIDS-Related Complex - drug therapy
/ AIDS-Related Complex - immunology
/ Antibodies, Bacterial - biosynthesis
/ Antibodies, Bacterial - blood
/ Bacterial Vaccines - immunology
/ Biological and medical sciences
/ Female
/ HIV
/ Humans
/ Male
